Canagliflozin and fracture risk in individuals with type 2 diabetes: results from the CANVAS Program

@article{Zhou2019CanagliflozinAF,
  title={Canagliflozin and fracture risk in individuals with type 2 diabetes: results from the CANVAS Program},
  author={Zien Zhou and Monica Jardine and Vlado Perkovic and David R Matthews and Kenneth W. Mahaffey and Dick de Zeeuw and Gregory R Fulcher and Mehul Desai and Richard Oh and Roger L. Simpson and Nelson B. Watts and Bruce Neal},
  journal={Diabetologia},
  year={2019},
  pages={1-14}
}
Aims/hypothesisAn increased risk of fracture with canagliflozin vs placebo was reported from the CANagliflozin cardioVascular Assessment Study (CANVAS) Program, with heterogeneity of findings identified between the two trials that comprise the CANVAS Program, CANVAS and CANVAS-R. The objective of these analyses was to identify reasons for the possibly different effects on fracture observed between CANVAS and CANVAS-R.MethodsThis study was an analysis of two highly similar trials, CANVAS and… CONTINUE READING

References

Publications referenced by this paper.
SHOWING 1-10 OF 25 REFERENCES

Canagliflozin and cardiovascular and renal events in type 2 diabetes.

  • Postgraduate medicine
  • 2018
VIEW 3 EXCERPTS
HIGHLY INFLUENTIAL